UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. EW, and raised its price target from $115.00 to $125.00. Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.” Edwards Lifesciences Corp. closed on Thursday at $102.88.